DGIdb - GLICLAZIDE Drug Record

GLICLAZIDE chembl:CHEMBL427216 Approved

Alternate Names:

GLICLAZIDE
NAZDOL MR
S-852
ZICRON PR
ZICRON
SE-1702
DIAMICRON
VITILE XL
ZICLASEG
DACADIS MR
J3.151H
DIAGLYK
EDICIL
GLIMIL
VAMJU
S-1702
BILXONA
DIAMICRON MR
N-(4-METHYLBENZENESULFONYL)-N'-(3-AZABICYCLO(3.3.0)OCT-3-YL)UREA
1-(3-AZABICYCLO(3.3.0)OCT-3-YL)-3-(P-TOLYLSULFONYL)UREA
GLICLAZIDA
GLIMICRON
GLICLAZIDUM
1-(HEXAHYDROCYCLOPENTA(C)PYRROL-2(1H)-YL)-3-(P-TOLYLSULFONYL)UREA
chemidplus:21187-98-4
chembl:CHEMBL427216
drugbank:01120
pubchem.compound:3475

Drug Info:

FDA Approval	not approved by the FDA
Drug Class	small molecule
Drug Indications	Hypoglycemic Agents
Drug Class	hypoglycemic agents
Year of Approval	not approved by the fda

(2 More Sources)

Publications:

Klen J et al., 2014, CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients., Eur J Clin Pharmacol
Sesti G et al., 2006, The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes., J Clin Endocrinol Metab
Gloyn AL et al., 2001, Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)., Diabet Med
Javorsky M et al., 2012, KCNJ11 gene E23K variant and therapeutic response to sulfonylureas., Eur J Intern Med
Li Q et al., 2014, KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients., Clin Exp Pharmacol Physiol
Proks et al., 2002, Sulfonylurea stimulation of insulin secretion., Diabetes
Reimann et al., 2001, Structural basis for the interference between nicorandil and sulfonylurea action., Diabetes
Gribble et al., 2000, Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues., Metab. Clin. Exp.
Harrower, 2000, Gliclazide modified release: from once-daily administration to 24-hour blood glucose control., Metab. Clin. Exp.
Lawrence et al., 2001, Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells., Diabetologia

GLICLAZIDE ABCC8

Interaction Score: 3.64

Interaction Types & Directionality:

binder

Interaction Info:

PMIDs:
12475777 11574406 11078468 11078469 11484080

Sources:
TTD
GLICLAZIDE KCNJ11

Interaction Score: 2.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24442125 16595597 11318841 22385882 25115353

Sources:
PharmGKB
GLICLAZIDE KCNJ1

Interaction Score: 1.59

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TEND
GLICLAZIDE G6PD

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
GLICLAZIDE CYP2C9

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24442125

Sources:
PharmGKB
GLICLAZIDE KDM4A

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

TEND: GLICLAZIDE
- Version: 01-August-2011
Alternate Names:

GLICLAZIDE Primary Drug Name

Drug Info:

Year of Approval not approved by the fda

Drug Class hypoglycemic agents

Publications:
TdgClinicalTrial: GLICLAZIDE
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Hypoglycemic Agents

Drug Class small molecule

FDA Approval not approved by the FDA

Publications:

PharmGKB: gliclazide

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Klen J et al., 2014, CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients., Eur J Clin Pharmacol

Sesti G et al., 2006, The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes., J Clin Endocrinol Metab

Gloyn AL et al., 2001, Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53)., Diabet Med

DTC: GLICLAZIDE
- Version: 02-September-2020
Alternate Names:

CHEMBL427216 ChEMBL Drug ID

Drug Info:

Publications:
TTD: Gliclazide
- Version: 2020.06.01
Alternate Names:

D0M2MR TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL427216
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	-
Novel drug target	Established target

GLICLAZIDE Drug Record

GLICLAZIDE chembl:CHEMBL427216 Approved

Alternate Names:

Drug Info:

Publications:

GLICLAZIDE ABCC8

Interaction Types & Directionality: binder

Interaction Info:

PMIDs: 12475777 11574406 11078468 11078469 11484080

Sources: TTD

GLICLAZIDE KCNJ11

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24442125 16595597 11318841 22385882 25115353

Sources: PharmGKB

GLICLAZIDE KCNJ1

Interaction Types & Directionality: n/a

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: None found

Sources: TdgClinicalTrial TEND

GLICLAZIDE G6PD

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

GLICLAZIDE CYP2C9

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24442125

Sources: PharmGKB

GLICLAZIDE KDM4A

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: DTC

TEND: GLICLAZIDE

Alternate Names: GLICLAZIDE Primary Drug Name

Drug Info: Year of Approval not approved by the fda Drug Class hypoglycemic agents

Publications:

TdgClinicalTrial: GLICLAZIDE

Alternate Names:

Drug Info: Drug Indications Hypoglycemic Agents Drug Class small molecule FDA Approval not approved by the FDA

Publications:

PharmGKB: gliclazide

Alternate Names:

Drug Info:

DTC: GLICLAZIDE

Alternate Names: CHEMBL427216 ChEMBL Drug ID

Drug Info:

Publications:

TTD: Gliclazide

Alternate Names: D0M2MR TTD Drug ID

Drug Info:

Publications:

ChemblDrugs: chembl:CHEMBL427216

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality:

binder

PMIDs:
12475777 11574406 11078468 11078469 11484080

Sources:
TTD

Interaction Types & Directionality:

n/a

PMIDs:
24442125 16595597 11318841 22385882 25115353

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
None found

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24442125

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC

Alternate Names:

GLICLAZIDE Primary Drug Name

Drug Info:

Year of Approval not approved by the fda

Drug Class hypoglycemic agents

Drug Info:

Drug Indications Hypoglycemic Agents

Drug Class small molecule

FDA Approval not approved by the FDA

Alternate Names:

CHEMBL427216 ChEMBL Drug ID

Alternate Names:

D0M2MR TTD Drug ID